Literature DB >> 15491291

Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.

S Vincent Rajkumar1, Robert A Kyle, Terry M Therneau, Raynell J Clark, Arthur R Bradwell, L Joseph Melton, Dirk R Larson, Matthew F Plevak, Jerry A Katzmann.   

Abstract

We hypothesized that the presence of monoclonal free light chains (FLC) in the serum of patients with monoclonal gammopathy of undetermined significance (MGUS) is a marker of clonal evolution and a risk factor for progression. Forty-seven patients with MGUS and documented progression to myeloma or related malignancy were compared with 50 age- and gender-matched patients with MGUS and no evidence of progression after 5 or more years of follow-up. The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001).

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15491291     DOI： 10.1111/j.1365-2141.2004.05169.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  16 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Authors:  Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

Review 3.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

4.  Appraisal of immunoglobulin free light chain as a marker of response.

Authors:  Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kimberly Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Journal:  Blood       Date:  2008-03-25       Impact factor: 22.113

5.  Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Authors:  S Kumar; L Zhang; A Dispenzieri; S Van Wier; J A Katzmann; M Snyder; E Blood; R DeGoey; K Henderson; R A Kyle; A R Bradwell; P R Greipp; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

Review 6.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

7.  Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.

Authors:  Sanjeev Sethi; Ladan Zand; Nelson Leung; Richard J H Smith; Dragan Jevremonic; Sandra S Herrmann; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

8.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

9.  Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.

Authors:  Trista Stankowski-Drengler; Morie A Gertz; Jerry A Katzmann; Martha Q Lacy; Shaji Kumar; Nelson Leung; Suzanne R Hayman; Francis Buadi; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

10.  Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies.

Authors:  Sandra Davern; Lian X Tang; Teresa K Williams; Sallie D Macy; Jonathan S Wall; Deborah T Weiss; Alan Solomon
Journal:  Am J Clin Pathol       Date:  2008-11       Impact factor: 2.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.